Alcyone Therapeutics
Andrew serves as Vice President of Product Development, responsible for overseeing an engineering development team and coordinating cross functionally across the organization, focused towards advancement of the Alcyone Therapeutics Precision Delivery portfolio. Andrew holds a B.S. in mechanical engineering and has over 18 years of experience bringing innovative technologies to the market, from concept, through regulatory clearance and product launch. Andrew also holds certificates in Medical Device Regulatory Affairs from Northeastern University and in Medical Device Management from Worcester Polytechnic Institute. Andrew first joined Alcyone to lead the development of a Hydrocephalus shunt technology, known as ReFlow, which was spun out to form Anuncia Inc. in 2018. Prior to joining Alcyone Therapeutics, Andrew held positions at Accellent Inc., now Integer (which later became Lake Region Medical) and Ranfac Corporation. Andrew holds numerous patents over a wide range of product families spanning over 18 years of cutting-edge technology development.
This person is not in any offices
Alcyone Therapeutics
Alcyone Therapeutics is a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions. Alcyone Therapeutics is advancing a pipeline of adeno-associated virus (AAV) gene therapy programs that leverage its proprietary, next-generation CNS delivery technology platform. Alcyone Therapeutics’ lead programs target the treatment of Rett syndrome and spinal muscular atrophy with respiratory distress type 1 (SMARD1).